A technique that transforms immune cells into cancer-seeking bloodhounds may overcome a roadblock that has hampered ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Almost four months ahead of schedule, Corcept Therapeutics' selective glucocorticoid receptor antagonist (SGRA) relacorilant ...
7don MSN
How a tryptophan-rich allosteric communication network helps activate a major drug target receptor
A multinational research team led by researchers at Institute of Science Tokyo, RIKEN, and the University of Toronto has ...
DelveInsight’s, “Hepatic Tumor Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and ...
UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...
A new approach engineers immune cells to recognize byproducts of cancer cells to trigger migration toward the tumor.
Pharmaceutical Technology on MSN
Corcept’s first-in-class ovarian cancer drug gains FDA approval
The drug can now be prescribed alongside nab-paclitaxel for patients with ovarian cancer who have relapsed between one and three times.
India has tightened surveillance on GLP-1 weight-loss drugs to curb misuse, unauthorized sales, and unethical promotion. The ...
All-cause mortality significantly lower with GLP-1 RA use, with consistent benefit across major cancer types, most GLP-1 RA types.
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that leverag ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results